Suppr超能文献

体外尿胱氨酸沉淀研究:胱氨酸肾结石的个体发生及内消旋-2,3-二巯基琥珀酸作为胱氨酸尿潜在治疗方法的鉴定。

Studies of urinary cystine precipitation in vitro: ontogeny of cystine nephrolithiasis and identification of meso-2,3-dimercaptosuccinic acid as a potential therapy for cystinuria.

作者信息

Parvex P, Rozen R, Dziarmaga A, Goodyer P

机构信息

Department of Nephrology, Geneva Children's Hospital, Geneva, Switzerland.

出版信息

Mol Genet Metab. 2003 Dec;80(4):419-25. doi: 10.1016/j.ymgme.2003.08.025.

Abstract

Children with fully recessive (Type I/I) cystinuria have a high risk of stone formation in the first decade of life. To assess the tendency for cystine to precipitate in individual urine samples, we developed an in vitro assay in which radiolabelled cystine (4mM) was dissolved in urine at 37 degrees C after alkalization to pH 10. Samples were then brought to pH 5, cooled, and centrifuged. The % decrease in supernatant cpm was used as a measure of cystine precipitation (CP). CP varied widely among normal children (74%+/-34) whereas variability of repeated determinations on a single adult individual was modest (64%+/-3.3). The assay was used to compare various potential therapies for cystinuria. Precipitation of exogenous cystine from normal urine was strongly inhibited by addition of D-penicillamine (CP: 8%+/-3) or dimercaptosuccinic acid (DMSA) (CP: 5%+/-1), at urinary concentrations attained by standard oral doses of each drug. Mercaptopropionylglycine (MPG) was moderately effective (CP: 43%+/-9), whereas captopril was a weak inhibitor (CP: 63%+/-12). Precipitation of endogenous cystine (2191 micromol/L) from a cystinuric patient showed that DMSA and D-penicillamine were again highly effective compared to the other agents. In addition DMSA and penicillamine added to the same patient's urine reduced the free cystine by 50% (as measured by automated amino acid analyzer) whereas MPG and captopril had no effect. In conclusion, DMSA is comparable to D-penicillamine as an in vitro inhibitor.

摘要

完全隐性(I/I型)胱氨酸尿症患儿在生命的第一个十年有很高的结石形成风险。为了评估胱氨酸在个体尿液样本中沉淀的倾向,我们开发了一种体外测定法,其中将放射性标记的胱氨酸(4mM)在碱化至pH 10后于37摄氏度溶解在尿液中。然后将样本调至pH 5,冷却并离心。上清液每分钟计数(cpm)的下降百分比用作胱氨酸沉淀(CP)的度量。正常儿童中CP差异很大(74%±34),而对单个成年人重复测定的变异性较小(64%±3.3)。该测定法用于比较胱氨酸尿症的各种潜在疗法。在每种药物标准口服剂量所达到的尿液浓度下,添加D-青霉胺(CP:8%±3)或二巯基琥珀酸(DMSA)(CP:5%±1)可强烈抑制正常尿液中外源胱氨酸的沉淀。2-巯基丙酰甘氨酸(MPG)有中等效果(CP:43%±9),而卡托普利是一种弱抑制剂(CP:63%±12)。来自一名胱氨酸尿症患者内源性胱氨酸(2191微摩尔/升)的沉淀表明,与其他药物相比,DMSA和D-青霉胺再次非常有效。此外,添加到同一名患者尿液中的DMSA和青霉胺使游离胱氨酸减少了50%(通过自动氨基酸分析仪测量),而MPG和卡托普利没有效果。总之,作为体外抑制剂,DMSA与D-青霉胺相当。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验